鉴定与cuproptosis相关的基因和免疫透在扩大心肌病的免疫透
Yixuan Lin1, Kaicong Chen1, Jinhua Guo2
1Department of Cardiology, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, China.
International journal of cardiology
|January 3, 2024
概括
与cuproptosis相关的六个新型基因被确定为扩张性心肌病 (DCM) 的潜在诊断生物标志物. 它们的表达与免疫细胞透相关,这表明cuproptosis在DCM中的作用.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 扩张性心肌病 (DCM) 是心力衰竭的主要原因.
- 在DCM病原发生中,cuproptosis的作用在很大程度上仍未被探索.
- 这项研究调查了与cuproptosis相关的基因作为DCM的潜在诊断标志物.
研究的目的:
- 确定与cuproptosis相关的基因作为DCM的诊断生物标志物.
- 探索这些基因,免疫透和心脏组织中药物点之间的关联.
- 阐明cuproptosis在DCM病理生理学中的潜在作用.
主要方法:
- 分析了来自非失败 (NF) 和DCM样本的基因表达数据.
- 用单个样本基因组丰富分析 (ssGSEA) 计算了cuproptosis评分.
- 权重基因共同表达网络分析 (WGCNA),随机森林和LASSO被用于识别特征基因.
- 使用ssGSEA和Cytoscape分析了免疫细胞透和调节网络.
主要成果:
- 通过WGCNA确定了8个基因模块,其中"MEblue"与cuproptosis和DCM有显著的关联.
- 建立了一个包括六个特征基因 (SEPTIN1,CLEC11A,ISG15,P3H3,SDSL和INKA1) 的诊断模型.
- 在DCM和NF组之间观察到免疫细胞透的显著差异.
- 根据特征基因构建了mRNA-miRNA-lncRNA和化学药物相互作用的调控网络.
结论:
- 六个基因 (SEPTIN1,CLEC11A,ISG15,P3H3,SDSL和INKA1) 被确定为DCM的新型诊断生物标志物.
- 这些基因的表达与DCM中的免疫细胞透有关.
- 质可能在扩张性心肌病的免疫调节中发挥作用.
相关概念视频
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...


